3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
246
Leukemia
185
Lymphoma
137
Leukemia, Myeloid, Acute
103
Burkitt Lymphoma
90
Myelodysplastic Syndromes
79
Lymphoma, Non-Hodgkin
65
Lymphoma, Large B-Cell, Diffuse
59
Breast Neoplasms
59
Leukemia, Lymphocytic, Chronic, B-Cell
49
Lymphoma, Mantle-Cell
47
Hodgkin Disease
47
Graft vs Host Disease
46
Lymphoma, Follicular
45
Leukemia, Myeloid, Accelerated Phase
45
Multiple Myeloma
39
Leukemia, Myeloid, Chronic-Phase
39
Congenital Abnormalities
39
Myeloproliferative Disorders
38
Blast Crisis
38
Leukemia, Myelomonocytic, Chronic
37
Leukemia, Biphenotypic, Acute
35
Recurrence
34
Lymphoma, Large-Cell, Immunoblastic
33
Lymphoma, B-Cell, Marginal Zone
31
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
30
Primary Myelofibrosis
27
Osteosarcoma
27
Neoplasms, Plasma Cell
25
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Interventions
Brentuximab Vedotin
4
Bexarotene
2
iratumumab
1
Vitamin B 12
1
Salvia hispanica seed extract
1
Methotrexate
1
Lenalidomide
1
Folic Acid
1
Cholecalciferol
1
10-propargyl-10-deazaaminopterin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma, Primary Cutaneous Anaplastic Large Cell
×
Methotrexate
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts